Compare Dyne Therapeutics Inc. Common Stock (DYN) vs H World Group Limited American Depositary Shares (HTHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs H World Group Limited American Depositary Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while H World Group Limited American Depositary Shares trades at $44.2 (market cap $14.16B). The key difference: H World Group Limited American Depositary Shares is far larger — about 5× Dyne Therapeutics Inc. Common Stock's market cap, and H World Group Limited American Depositary Shares pays a 4.91% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and H World Group Limited American Depositary Shares for 6 Days on average.
| DYN | HTHT | |
|---|---|---|
Market Cap | $2.81B | $14.16B |
Volume | 2,195,902 | 1,525,108 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $56.06 |
52-Week Low | $14.60 | $36.99 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.13B | $16.95B |
Dividend Yield | — | 4.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HTHT trades at $44.17, down 0.85% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.78 exceeding the $0.74 estimate. Revenue for 2025 was $25.31 billion, with a net income margin of 18.93% and robust ROE of 38.39%. Positive news highlights the asset-light model's margin improvement and a recent CNY bond offering.
The outlook remains positive with a consensus price target of $50.56, implying 14.5% upside, supported by earnings momentum and operational efficiency. Key risks include market saturation in China and reliance on domestic growth. Analyst sentiment is bullish with 11 buy ratings out of 19, though valuation multiples like a P/E of 31.46 warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About H World Group Limited American Depositary Shares
H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →
